Medicare Prior Authorization Getting WISeR? Five Essential Questions
On June 27, 2025, the Centers for Medicare and Medicaid Services introduced the WISeR model. This has generated an incredible number of discussions and questions. Here are answers to five of them.What is WISeR?What are the goals?
CMS wants to reduce fraud, abuse, and waste, including low-value care. The selected service codes no doubt are connected to these concerns. Here are just two examples.Why is CMS adding prior authorization to Original Medicare?
Contrary to a couple posts, prior authorization in Original Medicare is not new. Initially not part of the Social Security Act, the law was changed. Prior authorization has applied to Original Medicare for years.
For a long time, it focused mostly on power mobility devices (very prone to fraud) and procedures that might be considered cosmetic. For example, is rhinoplasty (nose surgery) necessary because the person can't breathe or selective because he doesn't like his nose? In 2020 and 2024, CMS expanded the list. Just as with the WISeR model, the current list of codes subject to authorization includes some with questionable medical necessity or low-value.Will this push Original Medicare closer to Medicare Advantage?
Some recent headlines reflect this concern.
'It's going to be just like Medicare Advantage, delay and deny.'
'CMS and insurers signed a pledge to reduce prior authorization and now they're doing this.'
There is no way to know for sure whether WISeR will turn Original Medicare into an Advantage clone. But that may not happen because there are some significant differences between this system and that of Medicare Advantage.Are there any big concerns?
With any new project, there will be concerns. Besides the one about pushing Original MC toward Advantage, here are three that pop up quite regularly:There is no denying something needs to be done to control the fraud and waste in Medicare. CMS recognizes that it will take to come up with a system and guardrails to achieve the goals while reducing provider burden and avoiding beneficiary harm. CMS has six years to get this right.
There is another WISER model. It stands for Watch, Pay attention, Interpret, Engage and Reflect, and helps to control strong emotions. It may be a wise thing to apply this model as we work through the CMS' attempt to become WISeR.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
21 minutes ago
- Fast Company
UnitedHealth Group confirms DOJ investigation over Medicare billing
BY UnitedHealth Group says it is cooperating with federal criminal and civil investigations involving its market-leading Medicare business. The health care giant said Thursday that it had contacted the Department of Justice after reviewing media reports about investigations into certain elements of its business. '(UnitedHealth) has a long record of responsible conduct and effective compliance,' the company said in a Securities and Exchange Commission filing. Earlier this year, The Wall Street Journal said federal officials had launched a civil fraud investigation into how the company records diagnoses that lead to extra payments for its Medicare Advantage, or MA, plans. Those are privately run versions of the government's Medicare coverage program mostly for people ages 65 and over. The company's UnitedHealthcare business covers more than 8 million people as the nation's largest provider of Medicare Advantage plans. The business has been under pressure in recent quarters due to rising care use and rate cuts. The Journal said in February, citing anonymous sources, that the probe focused on billing practices in recent months. The paper has since said that a federal criminal health care-fraud unit was investigating how the company used doctors and nurses to gather diagnoses that bolster payments. UnitedHealth said in the filing Thursday that it 'has full confidence in its practices and is committed to working cooperatively with the Department throughout this process.' UnitedHealth Group Inc. runs one of the nation's largest health insurance and pharmacy benefits management businesses. It also operates a growing Optum business that provides care and technology support. UnitedHealth raked in more than $400 billion in revenue last year as the third-largest company in the Fortune 500. Its share price topped $630 last fall to reach a new all-time high. But the stock has mostly shed value since December, when UnitedHealthcare CEO Brian Thompson was fatally shot in midtown Manhattan on his way to the company's annual investor meeting. A suspect, Luigi Mangione, has been charged in connection with the shooting. In April, shares plunged some more after the company cut its forecast due to a spike in health care use. A month later, former CEO Andrew Witty resigned, and the company withdrew its forecast entirely, saying that medical costs from new Medicare Advantage members were higher than expected. The stock price slipped another 3%, or $10.35, to $282.16 in midday trading Thursday. That represents a 55% drop from its all-time high. The Dow Jones Industrial Average, of which UnitedHealth is a component, also fell slightly. Meanwhile, the broader S&P 500 rose. UnitedHealth will report its second-quarter results next Tuesday. —Tom Murphy, AP health writer
Yahoo
42 minutes ago
- Yahoo
Why Are West Pharmaceutical Services (WST) Shares Soaring Today
What Happened? Shares of healthcare products company West Pharmaceutical Services (NYSE:WST) jumped 22.9% in the afternoon session after the company reported strong second-quarter 2025 financial results and raised its full-year outlook. The medical instruments supplier announced net sales of $766.5 million, a 9.2% increase from the prior year, which surpassed analyst expectations. The company's reported earnings per share (EPS) of $1.82 represented a significant beat over the consensus estimate of $1.51. In light of the strong performance, management increased its full-year 2025 financial outlook. West Pharmaceutical Services raised its net sales guidance to a range of $3.040 billion to $3.060 billion and lifted its adjusted-diluted EPS forecast to between $6.65 and $6.85. Additionally, the company's Board of Directors approved a fourth-quarter dividend of $0.22 per share. Is now the time to buy West Pharmaceutical Services? Access our full analysis report here, it's free. What Is The Market Telling Us West Pharmaceutical Services's shares are somewhat volatile and have had 10 moves greater than 5% over the last year. But moves this big are rare even for West Pharmaceutical Services and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 6 days ago when the stock dropped 6.3% on the news that several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively. Additionally, some pharmaceutical and biotech companies experienced sharp drops following unfavorable news; for instance, Sarepta Therapeutics plunged after a report indicated another patient death tied to its experimental gene therapy, and GSK's blood cancer drug dosage was voted against by the FDA advisory committee. Broader market sentiment, including concerns about rising costs and inadequate pricing for 2025 plans among health insurers, also contributed to the downward pressure on healthcare equities. West Pharmaceutical Services is down 15.9% since the beginning of the year, and at $276.29 per share, it is trading 20.6% below its 52-week high of $347.87 from January 2025. Investors who bought $1,000 worth of West Pharmaceutical Services's shares 5 years ago would now be looking at an investment worth $1,052. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
New York Post
an hour ago
- New York Post
UnitedHeath shares fall after health-care giant admits DOJ fraud probe into Medicare business
Shares of UnitedHealth Group slipped Thursday after the health-care giant said it was under a Department of Justice investigation. The company said it has started complying with both criminal and civil requests from federal investigators and it was cooperating with them. '(UnitedHealth) has a long record of responsible conduct and effective compliance,' the company said in a Securities and Exchange Commission filing. 3 UnitedHealth's UnitedHealthcare business covers more than 8 million people as the nation's largest provider of Medicare Advantage plans. wolterke – Earlier this year, The Wall Street Journal said federal officials had launched a civil fraud investigation into how the company records diagnoses that lead to extra payments for its Medicare Advantage, or MA, plans. Those are privately run versions of the government's Medicare coverage program mostly for people ages 65 and over. The company's UnitedHealthcare business covers more than 8 million people as the nation's largest provider of Medicare Advantage plans. The business has been under pressure in recent quarters due to rising care use and rate cuts. The Journal said in February, citing anonymous sources, that the probe focused on billing practices in recent months. The paper then said earlier this month that a federal criminal health care-fraud unit was investigating how the company used doctors and nurses to gather diagnoses that bolster payments. UnitedHealth Group said that it reached out to the Justice Department 'after reviewing media reports about investigations into certain aspects of the company's participation in the Medicare program.' 3 Earlier this year, The Wall Street Journal said federal officials had launched a civil fraud investigation into how the company records diagnoses that lead to extra payments for its Medicare Advantage, or MA, plans. AP UnitedHealth runs one of the nation's largest health insurance and pharmacy benefits management businesses. It also operates a growing Optum business that provides care and technology support. UnitedHealth raked in more than $400 billion in revenue last year as the third-largest company in the Fortune 500. Last year, its share price topped $630 to reach a new all-time high. But company shares have mostly shed value since December, when UnitedHealthcare CEO Brian Thompson was fatally shot in midtown Manhattan on his way to the company's annual investor meeting. A 26-year-old suspect, Luigi Mangione, has been charged in connection with the shooting. 3 A 26-year-old suspect, Luigi Mangione, has been charged in connection with last year's shooting of the head of the healthcare group. AP In April, shares plunged after the company cut its forecast due to a spike in health care use. A month later, former CEO Andrew Witty resigned and the company withdrew its forecast. The stock price slipped another 2%, or $5.12, to $287.39 Thursday morning. That represents a 54% drop from its all-time high. UnitedHealth will report its second-quarter results next Tuesday.
